Adenosine receptors as therapeutic targets
Open accessThe DOI matches its Crossref record; 215 of the 215 references it cites were found in a registry or an index.
Abstract
Adenosine receptors are major targets of caffeine, the most commonly consumed drug in the world. There is growing evidence that they could also be promising therapeutic targets in a wide range of conditions, including cerebral and cardiac ischaemic diseases, sleep disorders, immune and inflammatory disorders and cancer. After more than three decades of medicinal chemistry research, a considerable number of selective agonists and antagonists of adenosine receptors have been discovered, and some have been clinically evaluated, although none has yet received regulatory approval. However, recent advances in the understanding of the roles of the various adenosine receptor subtypes, and in the development of selective and potent ligands, as discussed in this review, have brought the goal of therapeutic application of adenosine receptor modulators considerably closer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among these, A1 and A2A receptors are considered the principal targets mediating caffeine’s physiological effects.”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [29]
In the citing paper
“A key mechanism underlying the interaction between caffeine and exercise is caffeine’s pharmacological action as a competitive adenosine receptor antagonist.”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [29]
In the citing paper
“Instead, competitive blockade of A1 and A2A adenosine receptors is widely regarded as the central mechanism underlying caffeine’s physiological effects during both habitual intake and exercise (Figure 1) [28,29,30,31].”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [29]
In the citing paper
“Within the range of plasma concentrations relevant to sports nutrition practice, typically micromolar levels achieved after low-to-moderate caffeine intake, caffeine’s primary mechanism of action is unlikely to involve phosphodiesterase (PDE) inhibition or direct intracellular Ca2+ release.”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [29]
In the citing paper
“This effect modulates key physiological processes such as anti-inflammatory responses, angiogenesis, and vasodilation, as illustrated in Figure 2 (left panel) [52,66,67,68].”
From Comparison of Polynucleotide and Polydeoxyribonucleotide in Dermatology: Molecular Mechanisms and Clinical Perspectives (2025) · cites this paper as [68]
Citations
Cites
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors
Fredholm, B. B., IJzerman, A. P., Jacobson, K. A., Klotz, K.-N., & Linden, J. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01511-4 · Cited by 2,585
Self-citationCalker, D. V., Müller, M., & Hamprecht, B. (1979) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1979.tb05236.x · Cited by 1,371
Ohta, A., & Sitkovsky, M. (2001) · Nature · doi:10.1038/414916a · Cited by 1,334
Astrocytic Purinergic Signaling Coordinates Synaptic Networks
Pascual, O., Casper, K. B., Kubera, C., Zhang, J., Revilla-Sanchez, R., Sul, J.-Y., Takano, H., Moss, S. J., McCarthy, K., & Haydon, P. G. (2005) · Science · doi:10.1126/science.1116916 · Cited by 1,280
Adenosine: A Mediator of the Sleep-Inducing Effects of Prolonged Wakefulness
Porkka-Heiskanen, T., Strecker, R. E., Thakkar, M., Bjørkum, A. A., Greene, R. W., & McCarley, R. W. (1997) · Science · doi:10.1126/science.276.5316.1265 · Cited by 1,252
Subclasses of external adenosine receptors.
Londos, C., Cooper, D. M., & Wolff, J. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.5.2551 · Cited by 1,081
Extracellular metabolism of ATP and other nucleotides
Zimmermann, H. (2000) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s002100000309 · Cited by 990
Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor
Ledent, C., Vaugeois, J.-M., Schiffmann, S. N., Pedrazzini, T., Yacoubi, M. E., Vanderhaeghen, J.-J., Costentin, J., Heath, J. K., Vassart, G., & Parmentier, M. (1997) · Nature · doi:10.1038/41771 · Cited by 918
Adenosine: an endogenous regulator of innate immunity
Haskó, G. (2004) · Trends in Immunology · doi:10.1016/j.it.2003.11.003 · Cited by 899
Research works printed but not linked: 1
- Ji, X. D. & Jacobson, K. A. [3H]-ZM241385 as a radioligand at recombinant human A2B adenosine receptors. Drug Des. Discov. 16, 217–226 (1999).
Cited by
Items 201–300 of 1,001
Limonene, a natural cyclic terpene, is an agonistic ligand for adenosine A2A receptors
Park, H. M., Lee, J. H., Jia, Y., Jun, H. J., & Lee, S. J. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.11.121 · Cited by 80
“AR subtypes are distributed in a tissue-specific manner [4].”
BackgroundLou, Q., Hansen, B. J., Fedorenko, O. Y., Csepe, T. A., Kalyanasundaram, A., Li, N., Hage, L. T., Glukhov, A. V., Billman, G. E., Weiss, R., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.007086 · Cited by 76
“Although adenosine leads to SAN dysfunction, it also ameliorates metabolic stress.(50) The double-edged role of adenosine”
BackgroundVarani, K., Massara, A., Vincenzi, F., Tosi, A., J, M. P. J., Trotta, F., & Borea, P. A. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24794 · Cited by 76
The Role of Adenosine Signaling in Headache: A Review
Fried, N. T., Elliott, M. B., & Oshinsky, M. L. (2017) · Brain Sciences · doi:10.3390/brainsci7030030 · Cited by 83
“Adenosine A1 and A3 receptors reduce cAMP levels, decreasing calcium conductance [1].”
BackgroundInfluentialAdenosine receptor desensitization and trafficking
Mundell, S. J., & Kelly, E. (2010) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.06.007 · Cited by 90
Cosyn, L., Palaniappan, K. K., Kim, S., Duong, H. T., Gao, Z., Jacobson, K. A., & Calenbergh, S. V. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0608208 · Cited by 90
Self-citationPurinergic Signaling in Mast Cell Degranulation and Asthma
Gao, Z., & Jacobson, K. A. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00947 · Cited by 76
“The roles of adenosine, P2X and P2Y receptors have been extensively investigated in both immune and non-immune cells (Jacobson and Gao, 2006; Chen et al., 2013; Burnstock and Boeynaems, 2014; Jacobson et al., 2015).”
BackgroundSelf-citationWolff, F., Loipetzberger, A., Gruber, W., Esterbauer, H., Aberger, F., & Frischauf, A. (2013) · Oncogene · doi:10.1038/onc.2013.343 · Cited by 83
Identification of zebrafish A2 adenosine receptors and expression in developing embryos
Boehmler, W., Petko, J., Woll, M. P., Frey, C., Thisse, B., Thisse, C., Canfield, V. A., & Levenson, R. G. (2008) · Gene Expression Patterns · doi:10.1016/j.gep.2008.11.006 · Cited by 94
“Adenosine is also a potent anti-inflammatory agent that plays an important role in tissue protection and repair (Jacobson and Gao, 2006).”
BackgroundThakur, S., Du, J., Hourani, S. M. O., Ledent, C. A., & Li, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.184606 · Cited by 79
Guo, D. M., Heitman, L. H., & IJzerman, A. P. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00025 · Cited by 86
Interplay of Hypoxia and A2B Adenosine Receptors in Tissue Protection
Koeppen, M., Eckle, T. D. L. G., & Eltzschig, H. K. (2011) · Advances in pharmacology · doi:10.1016/b978-0-12-385526-8.00006-0 · Cited by 81
Brennan, K. C., & Charles, A. C. (2009) · Seminars in Neurology · doi:10.1055/s-0029-1237113 · Cited by 83
“A product of the degradation of ATP, adenosine is primarily a local signaling molecule with inhibitory, vasodilatory, and cytoprotective roles, whose activity is linked (via ATP) to energy metabolism.(41) Adenosine has four receptor subtypes, A1, A2A, A2B, and A3, distributed in different anatomic locations, sometimes…”
BackgroundEmerging role of P2X7 receptors in CNS health and disease
Tewari, M., & Seth, P. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.10.001 · Cited by 83
Adenosine receptors interacting proteins (ARIPs): Behind the biology of adenosine signaling
Ciruela, F., Albergaria, C., Soriano, A., Cuffí, M. L., Carbonell, L., Sánchez, S., Gandía, J., & Fernández‐Dueñas, V. (2009) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2009.10.016 · Cited by 88
“Lastly, the A3R has also been found to be coupled to classical secondmessenger pathways such as inhibition of adenylyl cyclase, stimulation of PLC and calcium mobilization (for review see [2]) (Table 1).”
BackgroundInfluentialMitochondrial dysfunction in the fetoplacental unit in gestational diabetes mellitus
Sobrevía, L., Valero, P., Grismaldo, A., Villalobos-Labra, R., Pardo, F., Subiabre, M., Armstrong, G. A., Toledo, F., Vega, S., Cornejo, M., et al. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165948 · Cited by 81
Cannabidiol as a Novel Therapeutic for Immune Modulation
Peyravian, N., Deo, S. K., Daunert, S., & Jimenez, J. J. (2020) · ImmunoTargets and Therapy · doi:10.2147/itt.s263690 · Cited by 82
van der Putten, C., Zuiderwijk-Sick, E. A., van Straalen, L., de Geus, E. D., Boven, L. A., Kondova, I., IJzerman, A. P., & Bajramovic, J. J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803383 · Cited by 71
Crespo, A., Maatougui, A. E., Biagini, P., Azuaje, J., Coelho, A., Brea, J. M., Loza, M. I., Cadavid, M. I., García-Mera, X., Gutiérrez‐de‐Terán, H., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400185v · Cited by 77
Gao, Z.-G., Verzijl, D., Zweemer, A., Ye, K., Göblyös, A., IJzerman, A. P., & Jacobson, K. A. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.06.017 · Cited by 71
Self-citationAllosteric modulation of kinases and GPCRs: design principles and structural diversity
Lewis, J. A., Lebois, E. P., & Lindsley, C. W. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.02.014 · Cited by 77
Ciruela, F., Gómez‐Soler, M., Guidolin, D., Borroto‐Escuela, D. O., Agnati, L. F., Fuxé, K., & Fernández‐Dueñas, V. (2011) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2011.02.007 · Cited by 77
“Ultimately, the A3R has also been found to inhibit adenylyl cyclase, and to promote calciummobilization probably by direct G protein βγsubunits PLC activation (for review see [3]) (Table 1).”
BackgroundP1 receptors and cytokine secretion
Abbracchio, M. P., & Ceruti, S. (2007) · Purinergic Signalling · doi:10.1007/s11302-006-9033-z · Cited by 80
“These actions are mediated by the activation of four distinct adenosine re- M. P. Abbracchio (*) : S. Ceruti Laboratory of Molecular and Cellular Pharmacology of Purinergic Transmission, Department of Pharmacological Sciences, University of Milan, Via Balzaretti, 9, 20133 Milan, Italy e-mail: mariapia.abbracchio@unimi…”
BackgroundQuantification of adenosine A 1 receptor biased agonism: Implications for drug discovery
Baltos, J., Gregory, K. J., White, P. J., Sexton, P. M., Christopoulos, A., & May, L. T. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.11.013 · Cited by 78
Glial adenosine kinase – A neuropathological marker of the epileptic brain
Aronica, E., Sandau, U. S., Iyer, A., & Boison, D. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.01.028 · Cited by 70
“As a result, systemic administration of A1R agonists or ADK inhibitors successfully attenuates seizure activity (Fredholm, 2003; Jacobson and Gao, 2006; Boison, 2011).”
BackgroundAdenosine metabolism, immunity and joint health
Haskó, G., Antonioli, L., & Cronstein, B. N. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.02.002 · Cited by 85
“Adenosine is an endogenous purine nucleoside, a catabolite of ATP, that binds and activates one or more of four transmembrane G-proteincoupled cell surface adenosine receptors (R)s, which are A1R, A2AR, A2BR and A3R [1].”
InfluentialTherapeutic Perspectives of Adenosine Deaminase Inhibition in Cardiovascular Diseases
Kutryb-Zając, B. A., Mierzejewska, P., Slominska, E. M., & Smolenski, R. T. (2020) · Molecules · doi:10.3390/molecules25204652 · Cited by 70
“A1R and A3R predominantly activate heterotrimeric G proteins belonging to the Gα i/o family, which inhibit cAMP production by adenylate cyclase, in contrast A2AR and A2BR predominantly activate Gαs family members, which stimulate cAMP production [25].”
BackgroundSowa, N. A., Street, S. E., Vihko, P., & Zylka, M. J. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.2162-10.2010 · Cited by 74
“Since A1R is also coupled to PLC (Murthy and Makhlouf, 1995; Jacobson and Gao, 2006), this raises the question of why PAP inhibits TRPV1 following A1R activation, as we observed, instead of sensitizing TRPV1? This likely reflects differences in how pronociceptive GPCRs and A1R couple to downstream signaling pathways.”
BackgroundA2B Adenosine Receptor Induces Protective Antihelminth Type 2 Immune Responses
Patel, N. B., Wu, W., Mishra, P. K., Chen, F., Millman, A., Csóka, B., Koscsó, B., Eltzschig, H. K., Haskó, G., & Gause, W. C. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.02.001 · Cited by 70
“Adenosine is an endogenous purine nucleoside, a catabolite of ATP, and can regulate multiple physiological processes by binding to and activating one or more of four transmembrane adenosine G protein-coupled cell surface receptors, denoted A1, A2A, A2B, and A3 adenosine receptors (ARs) (Jacobson and Gao, 2006).”
BackgroundStructural Basis for Binding of Allosteric Drug Leads in the Adenosine A1 Receptor
Miao, Y., Bhattarai, A., Nguyen, A. T. N., Christopoulos, A., & May, L. T. (2018) · Scientific Reports · doi:10.1038/s41598-018-35266-x · Cited by 71
Modulation of metalloproteinase-9 in U87MG glioblastoma cells by A3 adenosine receptors
Gessi, S., Sacchetto, V., Fogli, E., Merighi, S., Varani, K., Baraldi, P. G., Tabrizi, M. A., Leung, E., MacLennan, S., & Borea, P. A. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.01.009 · Cited by 71
Discovery of Potent and Highly Selective A 2B Adenosine Receptor Antagonist Chemotypes
Maatougui, A. E., Azuaje, J., Gómez, M. A. G., Miguez, G., Crespo, A., Carbajales, C., Escalante, L., García-Mera, X., Gutiérrez‐de‐Terán, H., & Sotelo, E. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01586 · Cited by 69
Molecular Dynamics Simulations Reveal Insights into Key Structural Elements of Adenosine Receptors
Rodriguez, D. J., Piñeiro, Á., & Gutiérrez‐de‐Terán, H. (2011) · Biochemistry · doi:10.1021/bi200100t · Cited by 69
Therapeutic epilepsy research: From pharmacological rationale to focal adenosine augmentation
Boison, D., & Stewart, K.-A. A. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.08.005 · Cited by 74
“Likewise, adenosine A1R agonists are very effective in the inhibition of neuronal activity and in the suppression of seizures [25] and have been the subject of intense drug development efforts [37-39].”
BackgroundIncreased sensitivity to apoptosis induced by methotrexate is mediated by JNK
Spurlock, C. F., Aune, Z. T., Tossberg, J. T., Collins, P. L., Aune, J. P., Huston, J. W., Crooke, P. S., Olsen, N. J., & Aune, T. M. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30457 · Cited by 74
Pugliese, A. M., Coppi, E., Volpini, R., Cristalli, G., Corradetti, R., Jeong, L. S., Jacobson, K. A., & Pedata, F. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.06.003 · Cited by 74
“On the whole, the data support the wellestablished neuroprotective role of A1 receptors [9,12,41] and confirm an opposite, deleterious, role of A3 receptors during prolonged ischemia [14].”
BackgroundResultSelf-citationSowa, N. A., Voss, M. K., & Zylka, M. J. (2010) · Molecular Pain · doi:10.1186/1744-8069-6-20 · Cited by 68
“These agonists are often delivered intrathecally to avoid side effects associated with peripheral A1R activation [42].”
BackgroundEl‐Tayeb, A., Iqbal, J., Behrenswerth, A., Romio, M., Schneider, M., Zimmermann, H., Schrader, J., & Müller, C. E. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900538v · Cited by 72
Neuromodulatory Effects of Guanine-Based Purines in Health and Disease
Tasca, C. I., Lanznaster, D., de Oliveira, K. A., Fernández‐Dueñas, V., & Ciruela, F. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00376 · Cited by 78
“Since then, adenosine and ATP have been considered to be important neuromodulators in the central nervous system (CNS; Cunha, 2005; Jacobson and Gao, 2006; Burnstock et al., 2011; Tozaki-Saitoh et al., 2011; Ciruela et al., 2012).”
BackgroundNovel thiazole derivatives: a patent review (2008 – 2012. Part 2)
Leoni, A., Locatelli, A., Morigi, R., & Rambaldi, M. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.910196 · Cited by 69
“The potential of A1 antagonists for the treatment of congestive heart failure is well documented in the literature [69].”
BackgroundVeras, F. P., Peres, R. S., Saraiva, A. L., Pinto, L. G., Louzada‐Júnior, P., Cunha, T. M., Paschoal, J. A. R., Cunha, F. Q., & Alves-Filho, J. C. (2015) · Scientific Reports · doi:10.1038/srep15171 · Cited by 68
An emerging role for adenosine and its receptors in bone homeostasis
Ham, J., & Evans, B. A. J. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00113 · Cited by 80
“Adenosine receptors have long been considered to be possible therapeutic targets in a wide range of conditions including cardiac, pulmonary, immunological, and inflammatory disorders (Fredholm,2003,2010; Jacobson and Gao,2006).”
BackgroundGuo, D. M., van Dorp, E. J. H., Mulder‐Krieger, T., van Veldhoven, J. P. D., Brussee, J., IJzerman, A. P., & Heitman, L. H. (2012) · SLAS DISCOVERY · doi:10.1177/1087057112464776 · Cited by 77
“The A 1 R is a promising therapeutic target since it has clinical relevance in neurological disorders, such as cognition deficits, and is involved in cardiovascular preconditioning.(14,15) A tool compound— namely, FSCPX—was used to set up the dual-point screening assay since it is a known irreversibly binding antagoni…”
MethodPurinergic regulation of neutrophil chemotaxis
JUNGER, W. G. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8095-1 · Cited by 68
Doengi, M., Deitmer, J. W., & Lohr, C. (2008) · The FASEB Journal · doi:10.1096/fj.07-101782 · Cited by 78
Yang, Y., Lightstone, F. C., & Wong, S. E. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.749853 · Cited by 65
“[74] mapped the hydration sites and studied the thermodynamic profiles for the GPCR adenosine A2A (A2A) receptor [75] in order to explain the interesting and confusing SARs between triazolylpurine analogs and the A2A receptor [76].”
Regulation of Foam Cells by Adenosine
Reiss, A. B., & Cronstein, B. N. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.226878 · Cited by 69
Current Status and Challenges Associated with CNS-Targeted Gene Delivery across the BBB
Kimura, S., & Harashima, H. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121216 · Cited by 65
“including CNS disorders [280], and it has been reported that the activation of adenosine receptors could elevate the permeability of the BBB in vivo [279].”
BackgroundBinder, D. K., & Steinhäuser, C. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03236-x · Cited by 73
Allosteric modulation of adenosine receptors
Göblyös, A., & IJzerman, A. P. (2010) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.06.013 · Cited by 73
Martins, D. F., Mazzardo‐Martins, L., Soldi, F., Stramosk, J., Piovezan, A. P., & Santos, A. R. S. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2012.12.042 · Cited by 64
“It is reformed into ATP via adenosine kinase, while excess d. amounts are enzymatically converted via adenosine deaminase in the purine catabolic pathway sequence, to inosine, hypoxanthine, xanthine and finally uric acid (Jacobson and Gao, 2006).”
Zhang, Y., Li, M., Kang, R., Shi, J., Liu, G.-T., & Zhang, J. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.06.002 · Cited by 65
“DPMA, a potent agonist for the A 2A adenosine receptors, is also a N 6 -substituted adenosine derivative (Jacobson and Gao, 2006).”
Structural features of adenosine receptors: From crystal to function
Piirainen, H., Ashok, Y., Nanekar, R. T., & Jaakola, V. (2010) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.05.021 · Cited by 81
“Ala Agonist No effect CGS21680, CADO, DPMA, NECA, R-PIA, IB-MECA [40]”
BackgroundAdenosine receptors and second messenger signaling pathways in rat cardiac fibroblasts
Epperson, S. A., Brunton, L. L., Ramírez‐Sánchez, I., & Villarreal, F. J. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00290.2008 · Cited by 70
Targeting of adenosine receptors in ischemia–reperfusion injury
Laubach, V. E., French, B. A., & Okusa, M. D. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.541441 · Cited by 69
“First, potent and selective synthetic agonists and antagonists for each adenosine receptor have been developed to enable researchers to specifically test the role of each receptor in almost any model [50].”
BackgroundOcular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye
Cheng, K., Hsieh, C., Nepali, K., & Liou, J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01033 · Cited by 73
Topical treatment of glaucoma: established and emerging pharmacology
Dikopf, M. S., Vajaranant, T. S., & Edward, D. P. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1328498 · Cited by 65
“the four types of adenosine receptors varies [106].”
BackgroundCaffeine Consumption and the Risk of Breast Cancer in a Large Prospective Cohort of Women
Ishitani, K., Lin, J., Manson, J. E., Buring, J. E., & Zhang, S. M. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.18.2022 · Cited by 67
“Caffeine is a known antagonist of the adenosine receptor.(2,57) Adenosine, an endogenous bioactive substance, exerts its diverse biological effects through the activation of specific cell surface adenosine receptor.”
Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions
Donegan, R. K., & Lieberman, R. L. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00828 · Cited by 66
The Ion Channel and GPCR Toolkit of Brain Capillary Pericytes
Hariharan, A., Weir, N., Robertson, C., He, L., Betsholtz, C., & Longden, T. A. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.601324 · Cited by 68
“The ion channels and GPCRs that are highly expressed by brain pericytes thus have the potential to be pharmacological targets for vascular disorders, metabolic diseases, and neurodegenerative and neurological disorders (wherein for example KATP channels, IP3Rs, VDCCs, TRP channels, and GPCRs such as A2A and ETA recept…”
BackgroundHirota, T., & Kishi, T. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.06.038 · Cited by 64
“Among the four adenosine receptors, A1, A2A, A2B, and A3, the A1 and A2A receptors are mainly expressed in the human central nervous system (Jacobson and Gao, 2006).”
BackgroundPugliese, A. M., Traini, C., Cipriani, S., Gianfriddo, M., Mello, T., Giovannini, M. G., Galli, A., & Pedata, F. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00218.x · Cited by 69
Recent Advances in Dendrimer Research for Cardiovascular Diseases
Yu, M., Xu, J., Xu, L., Chen, C., Shen, W., Cao, Y., Lian, G., & Qi, R. (2015) · Biomacromolecules · doi:10.1021/acs.biomac.5b00979 · Cited by 61
Liu, L., Chen, Q., Wen, L., Li, C., Qin, H., & Xing, D. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201808601 · Cited by 64
Cell-Type Apoptosis in Lung during SARS-CoV-2 Infection
Liu, Y., Garron, T. M., Chang, Q., Su, Z., Zhou, C., Qiu, Y., Gong, E. C., Zheng, J., Yin, Y. W., Ksiazek, T. G., et al. (2021) · Pathogens · doi:10.3390/pathogens10050509 · Cited by 62
“The cAMP-EPAC signaling axes play various roles in regulating cell apoptosis in different cells [33,34].”
BackgroundElzein, E. O., Kalla, R. V., Li, X., Perry, T. D., Gimbel, A., Zeng, D., Lustig, D. A., Leung, K., & Zablocki, J. A. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7014815 · Cited by 65
Adenosine Receptors: What We Know and What We are Learning
Trincavelli, M. L., Daniele, S., & Martini, C. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610791268756 · Cited by 70
Pyrimidine Derivatives as Potent and Selective A3Adenosine Receptor Antagonists
Yaziji, V., Rodriguez, D. J., Gutiérrez‐de‐Terán, H., Coelho, A., Caamaño, O., García-Mera, X., Brea, J. M., Loza, M. I., Cadavid, M. I., & Sotelo, E. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100843z · Cited by 66
Associations Between Caffeine Consumption, Cognitive Decline, and Dementia: A Systematic Review
Chen, J. Q. A., Scheltens, P., Groot, C., & Ossenkoppele, R. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-201069 · Cited by 59
“By blocking adenosine receptors, caffeine is capable of exerting effects on metabolism, the cardiovascular system, the respiratory system, and neuroinflammatory, neuromodulatory, and neuroprotective processes [10, 11].”
BackgroundAlvarez, C. L., Troncoso, M. F., & Espelt, M. V. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30580 · Cited by 63
“The activation of these receptors occurs through the activation or inhibition of G protein acting through the Gi/o protein subunits in A1 and A3A receptors and through Gs/ olf in A2A and A2B receptors (Jacobson & Gao, 2006; Sheth et al., 2014).”
MethodA3 Adenosine Receptor: Pharmacology and Role in Disease
Borea, P. A., Gessi, S., Bar‐Yehuda, S., & Fishman, P. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-89615-9_10 · Cited by 61
Adenosine and the Auditory System
Vlajkovic, S. M., Housley, G. D., & Thorne, P. R. (2009) · Current Neuropharmacology · doi:10.2174/157015909789152155 · Cited by 62
“All four adenosine receptors couple to ERK1/2 MAPK [48], whilst A2B and A3 receptors can also activate JNK and p38 [29,39].”
BackgroundInfluentialCosimelli, B., Greco, G., Ehlardo, M., Novellino, E., Settimo, F. D., Taliani, S., Motta, C. L., Bellandi, M., Tuccinardi, T., Martinelli, A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701159t · Cited by 62
2-Aminothienopyridazines as Novel Adenosine A1Receptor Allosteric Modulators and Antagonists
Ferguson, G. N., Valant, C., Horne, J., Figler, H., Flynn, B. L., Linden, J. M., Chalmers, D. K., Sexton, P. M., Christopoulos, A., & Scammells, P. J. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800557d · Cited by 65
Geldenhuys, W. J., & Van der Schyf, C. J. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.744746 · Cited by 57
“Closer inspection of the activities associated with this neuroprotection indicated that CSC is able to act as a neuroprotective compound through adenosine A2 receptor antagonism [53,54] and MAO-B inhibition: adenosine A1 receptors did not seem to play a role in the neuroprotective activity of caffeinyl-type compounds.”
BackgroundIdentification of A3adenosine receptor agonists as novel non‐narcotic analgesics
Janes, K., Symons-Liguori, A. M., Jacobson, K. A., & Salvemini, D. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13446 · Cited by 73
“Lastly, vasodilator A2A receptors expressed on the epithelium of coronary blood vessels is of notewith respect to the cardiovascular side effects of A2A-specific agents (Jacobson and Gao, 2006; Gao and Jacobson, 2007; Fredholm et al., 2011).”
BackgroundSelf-citationNew paradigms in adenosine receptor pharmacology: allostery, oligomerization and biased agonism
Vecchio, E. A., Baltos, J., Nguyen, A. T. N., Christopoulos, A., White, P. J., & May, L. T. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14337 · Cited by 64
“The A3 receptors, viaGi/o coupling, activate PLC and Ca2+ signalling through the Gβγ and activates KATP channel opening in the myocardium (Jacobson and Gao, 2006).”
BackgroundInfluentialNovel Anti-Melanogenesis Properties of Polydeoxyribonucleotide, a Popular Wound Healing Booster
Noh, T., Chung, B., Kim, S., Lee, M., Kim, M., Youn, C., Lee, M., & Chang, S. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091448 · Cited by 68
“Adenosine is a purine nucleoside released from a variety of cells in response to a range of stressors [19].”
BackgroundNon-dopaminergic approaches to the treatment of motor complications in Parkinson's disease
Cenci, M. A., Skovgård, K., & Odin, P. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109027 · Cited by 66
Drugs targeting adenosine signaling pathways: A current view
Kutryb-Zając, B. A., Kawecka, A., Nasadiuk, K., Braczko, A., Stawarska, K., Caiazzo, E., Koszałka, P., & Cicala, C. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115184 · Cited by 64
Chimote, A. A., Hajdú, P., Kucher, V., Boiko, N., Kuras, Z., Szilágyi, O., Yun, Y., & Conforti, L. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300702 · Cited by 64
Colotta, V., Catarzi, D., Varano, F., Capelli, F., Lenzi, O., Filacchioni, G., Martini, C., Trincavelli, M. L., Ciampi, O., Pugliese, A. M., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070123v · Cited by 63
P2X7 receptor‐induced death of motor neurons by a peroxynitrite/FAS‐dependent pathway
Gandelman, M., Levy, M., Cassina, P., Barbeito, L., & Beckman, J. S. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12286 · Cited by 57
Novel Ergopeptides as Dual Ligands for Adenosine and Dopamine Receptors
Vendrell, M., Angulo-Pueyo, E., Casadó, V., Lluís, C., Franco, R., Alberício, F., & Royo, M. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm060947x · Cited by 60
Gaussian accelerated molecular dynamics for elucidation of drug pathways
Bhattarai, A., & Miao, Y. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1538207 · Cited by 56
“Four subtypes of class A GPCRs (the A 1 , A 2A , A 2B and A 3 ) mediate the effects of adenosine and play key roles in physiological functions [65].”
BackgroundThe adenosine A2B G protein-coupled receptor: Recent advances and therapeutic implications
Vecchio, E. A., White, P. J., & May, L. T. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.01.003 · Cited by 61
Medicinal Chemistry of the A3 Adenosine Receptor: Agonists, Antagonists, and Receptor Engineering
Jacobson, K. A., Klutz, A. M., Tosh, D. K., Ivanov, A. A., Preti, D., & Baraldi, P. G. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-89615-9_5 · Cited by 61
“Nevertheless, many of the nucleoside analogs that were shown to be rat A3AR agonists, including Cl–IB–MECA and IB–MECA, were later found to be moderately selective for the human A3AR after it was cloned (Jacobson and Gao, 2006; Salvatore et al. 1993).”
BackgroundSelf-citationRybaczyk, L. A., Rozmiarek, A., Circle, K. C., Grants, I. S., NEEDLEMAN, B. J., Wunderlich, J. E., Huang, K., & Christofi, F. L. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20893 · Cited by 57
Investigation of esophageal sensation and biomechanical properties in functional chest pain
Nasr, I., attaluri, A., Hashmi, S. M. A., Gregersen, H. N., & Rao, S. S. C. (2010) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2009.01451.x · Cited by 61
Catarzi, D., Colotta, V., Varano, F., Poli, D., Squarcialupi, L., Filacchioni, G., Varani, K., Vincenzi, F., Borea, P. A., Ben, D. D., et al. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.10.031 · Cited by 58
Tosh, D. K., Phan, K., Gao, Z., Gakh, A. A., Xu, F., Deflorian, F., Abagyan, R. A., Stevens, R. C., Jacobson, K. A., & Katritch, V. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300095s · Cited by 56
Self-citationPotential for Developing Purinergic Drugs for Gastrointestinal Diseases
Ochoa‐Cortés, F., Liñán-Rico, A., Jacobson, K. A., & Christofi, F. L. (2014) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000047 · Cited by 62
Self-citationSanjani, M. S., Teng, B., Krahn, T., Tilley, S., Ledent, C. A., & Mustafa, S. J. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00052.2011 · Cited by 59
“protecting against ischemic damage (37).”
BackgroundGöblyös, A., Gao, Z., Brussee, J., Connestari, R., Santiago, S. N., Ye, K., IJzerman, A. P., & Jacobson, K. A. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060086s · Cited by 63
“Condensation of anthranilic acid hydrochloride (1) with 2-nitro-acetaldehyde-oxim (HON=CHCH2NO2), prepared in situ from CH3NO2 and NaOH20, resulted in 2-(2-nitro-ethylideneamino)-benzoic acid (2), which was dehydrated in acetic anhydride in the presence of potassium acetate to give 3-nitro-4-hydroxyquinoline (3).”
MethodSelf-citationLenzi, O., Colotta, V., Catarzi, D., Varano, F., Filacchioni, G., Martini, C., Trincavelli, M. L., Ciampi, O., Varani, K., Marighetti, F., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060373w · Cited by 56
Regulation of neurite outgrowth by Gi/o signaling pathways
Kenneth, D. B. (2008) · Frontiers in bioscience · doi:10.2741/3022 · Cited by 68
“Adenosine receptors are one of the main targets in the brain for caffeine, and there are several agonists and antagonists currently being evaluated for clinical use (116).”
BackgroundInfluentialLambertucci, C., Antonini, I., Buccioni, M., Ben, D. D., Kachare, D. D., Volpini, R., Klotz, K., & Cristalli, G. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.02.030 · Cited by 66
Jeong, L. S., Pal, S., Choe, S. A., Choi, W. J., Jacobson, K. A., Gao, Z., Klutz, A. M., Hou, X., Kim, H. O., Lee, H. W., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8008647 · Cited by 55
“6-Chloro-9-((3aR,4R,6aS)-2,2-dimethyltetrahydrothieno[3,4-d][1,3]dioxol-4-yl)-9Hpurine (9): 6-Chloropurine (3.”
Self-citationLouvel, J., Guo, D. M., Agliardi, M., Mocking, T. A. M., Kars, R., Pham, T. P., Xia, L., de Vries, H., Brussee, J., Heitman, L. H., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401643m · Cited by 58
Nguyen, A. T. N., Baltos, J., Thomas, T., Nguyen, T. D., Muñoz, L. L., Gregory, K. J., White, P. J., Sexton, P. M., Christopoulos, A., & May, L. T. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.105007 · Cited by 55
Metadata
- Authors
- Jacobson, K. A., & Gao, Z.-G.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Jacobson, Kenneth A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-03
- Volume
- 5
- Issue
- 3
- Pages
- 247-264
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC3463109
- OpenAlex
- W1985598247
- Cited by
- 1,431
- References
- 215
- Citations by year
- 2026: 34 · 2025: 50 · 2024: 52 · 2023: 55 · 2022: 80 · 2021: 58 · 2020: 65 · 2019: 79 · 2018: 66 · 2017: 59 · 2016: 65 · 2015: 64 · 2014: 80 · 2013: 80 · 2012: 83
- FWCI
- 5.66
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (Z01DK031117)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- adenosine receptors, adenosine receptor agonists, adenosine receptor antagonists, selective ligands, caffeine, cardiovascular disease, ischemic diseases, sleep disorders, inflammatory diseases, cancer, neurological disorders, drug development
- MeSH terms
- Animals, Disease, Drug Therapy, Humans, Ligands, Structure-Activity Relationship, Molecular Structure, Signal Transduction, Receptors, Purinergic P1, Purinergic P1 Receptor Agonists, Purinergic P1 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.